Elzonris Dosage & Drug Information

Information is sourced from publicly available references. The information is for educational purpose of healthcare professionals and we are not liable for any loss or damage.

Core Prescribing Info

Contents

Tagraxofusp

Indications/Uses

Monotherapy for 1st-line treatment of blastic plasmacytoid dendritic cell neoplasm (BPDCN) in adults.

Dosage/Direction for Use

IV Adult BPDCN 12 mcg/kg once daily over 15 min on days 1-5 of 21-day cycle. Premed w/ H₁- & H₂-histamine antagonist, corticosteroid & acetaminophen approx 60 min prior to each infusion.

MIMS Class

Targeted Cancer Therapy

ATC Classification

L01XX67 - tagraxofusp ; Belongs to the class of other antineoplastic agents. Used in the treatment of cancer.

Regulatory Classification

POM

Presentation/Packing

Form

Elzonris conc for soln for infusion 1,000 mcg/mL

Packing/Price

1's

Elzonris

Manufacturer:

Alcami Carolinas Corporation